Abemaciclib and Letrozole to Treat Endometrial Cancer

Summary

This is a phase II single arm trial to determine the percentage of patients without evidence of disease progression on abemaciclib and letrozole in advanced stage, persistent or recurrent endometrioid endometrial cancer at 6 months. Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.

Timeline

Start

2020-10-10

Primary completion

2026-12-01

Completion

2026-12-31

Drugs

Indications